Comparative Pharmacology
Head-to-head clinical analysis: LIDOPEN versus NESACAINE MPF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOPEN versus NESACAINE MPF.
LIDOPEN vs NESACAINE-MPF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is a sodium channel blocker, stabilizing neuronal membranes by inhibiting the influx of sodium ions, thereby preventing the propagation of action potentials and producing local anesthesia.
Nesacaine-MPF (chloroprocaine) is an ester-type local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx, thereby blocking impulse conduction in nerve fibers.
Lidocaine 2% topical gel: Apply 1-2 grams (approximately 5-10 cm ribbon) to affected area every 4-6 hours as needed, not to exceed 5 grams per day. For infiltration anesthesia: 1% solution, 0.5-5 mL injected locally; maximum 4.5 mg/kg.
1% solution: 2.5-30 mL (25-300 mg) subcutaneously or locally; maximum 30 mL per dose. 2% solution: 1.25-15 mL (25-300 mg) subcutaneously or locally; maximum 15 mL per dose.
None Documented
None Documented
1.5–2 hours (terminal); prolonged in hepatic impairment
Terminal half-life: 3-4 hours (adults); prolonged in hepatic or renal impairment.
Renal (10% unchanged; 80% as metabolites), biliary/fecal (10%)
Renal excretion of metabolites; <10% unchanged drug. Biliary/fecal elimination minor.
Category C
Category C
Local Anesthetic
Local Anesthetic